OncoPep
OncoPep develops a multi-peptide therapeutic vaccine to prevent the progression of cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $11.0m | Series D | |
| Total Funding | 000k | ||
Related Content
OncoPep is a biotechnology company focused on developing innovative cancer vaccines aimed at preventing the progression of various cancers, including multiple myeloma and triple-negative breast cancer (TNBC). The company operates in the biopharmaceutical market, primarily serving cancer patients and healthcare providers. OncoPep's business model revolves around the research, development, and clinical testing of its lead investigational vaccine, PVX 410, which is designed to stimulate the patient's immune system to combat cancer cells. The company generates revenue through partnerships, grants, and potential future sales of its vaccines upon regulatory approval. Currently, PVX 410 is in Phase 2 clinical trials for smoldering multiple myeloma (SMM) and is being evaluated for its efficacy both as a standalone treatment and in combination with other immunomodulatory agents.
Keywords: cancer vaccines, multiple myeloma, TNBC, immunotherapy, PVX 410, clinical trials, biopharmaceutical, oncology, immune system, targeted therapy.